Expertise in
6
conditions

Dr. Christopher Moertel

Hematology | Oncology
University Of Minnesota Medical Center Fairview Riverside
2450 Riverside Ave, 
Minneapolis, MN 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
6
conditions
University Of Minnesota Medical Center Fairview Riverside
2450 Riverside Ave, 
Minneapolis, MN 

Overview

Christopher Moertel is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota.

Dr. Moertel is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, and RASopathies.

He is actively involved in clinical research, co-authoring 57 peer reviewed articles and participating in 15 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in MN

Hospital Affiliations

M Health Fairview University Of Mn Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
View 10 Less Insurance Carriers -

Locations

University of Minnesota Medical Center Fairview Riverside
2450 Riverside Ave, Minneapolis, MN 55454

Additional Areas of Focus

Dr. Moertel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: April 14, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Enrollment Status: Recruiting
Publish Date: March 09, 2026
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2026
Intervention Type: Drug
Study Drugs: BGB-290, Temozolomide
Study Phase: Phase 1
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: February 17, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug, Radiation, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine
Study Phase: Phase 3
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Other, Procedure
View 8 Less Clinical Trials

57 Total Publications

Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 19, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Paul Orchard
Hematology | Oncology
Expertise in
17
conditions
Dr. Paul Orchard
Hematology | Oncology

University Of Minnesota Masonic Children's Hospital

420 Delaware St SE, 
Minneapolis, MN 
 (0.4 miles away)
612-626-2313
Languages Spoken:
English
See accepted insurances

Paul Orchard is a Pediatric Hematologist Oncologist and a Pediatrics specialist in Minneapolis, Minnesota. He has been an author on 166 peer reviewed articles and participated in 18 clinical trials in the past 15 years. He is licensed to treat patients in MN. Dr. Orchard is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Adrenoleukodystrophy (ALD), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Mucopolysaccharidoses (MPS), Bone Marrow Transplant, and Osteotomy. Dr. Orchard is board certified in Pediatrics.

Expertise in
14
conditions
Dr. Margaret Macmillan
Hematology | Oncology
Expertise in
14
conditions
Dr. Margaret Macmillan
Hematology | Oncology

University Of Minnesota Medical Center Fairview Riverside

2450 Riverside Ave, 
Minneapolis, MN 
 (0.1 miles away)
612-365-4100
Languages Spoken:
English
See accepted insurances

Margaret Macmillan is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Macmillan is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Congenital Aplastic Anemia, Fanconi Anemia, Graft Versus Host Disease (GvHD), Aplastic Anemia, and Bone Marrow Transplant.

Expertise in
30
conditions
Dr. Mark Reding
Hematology | Oncology
Expertise in
30
conditions
Dr. Mark Reding
Hematology | Oncology

Fairview Pharmacy Hemophilia Services

2512 S 7th St Ste 105, 
Minneapolis, MN 
 (0.3 miles away)
612-273-5005
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Reding is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Reding is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Blood Clots, Hemophilia B, Splenectomy, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Christopher Moertel

How do I make an appointment with Dr. Christopher Moertel?

You can book an appointment with Dr. Christopher Moertel by calling their office at 612-365-8100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Christopher Moertel a top-rated expert for Neurofibromatosis Type 1 (NF1)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christopher Moertel is classified as an Elite expert for Neurofibromatosis Type 1 (NF1), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Christopher Moertel specialize in?

While Dr. Christopher Moertel is a Hematology, they have specific expertise in Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Malignant Peripheral Nerve Sheath Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Christopher Moertel participate in research or clinical trials?

Yes. Dr. Christopher Moertel has published 57 articles and abstracts on conditions like Neurofibromatosis Type 1 (NF1). You can view a list of Dr. Christopher Moertel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Christopher Moertel accept my insurance?

Dr. Christopher Moertel accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 612-365-8100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moertel's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile